Bewertung der Wirksamkeit und Sicherheit von HLX10 + Chemotherapie (Carboplatin-Etoposid) bei US-Patienten mit ES-SCLC
Eine randomisierte, offene Studie zur HLX10-Plus-Chemotherapie (Carboplatin-Etoposid) im Vergleich mit Atezolizumab-Plus-Chemotherapie bei zuvor unbehandelten US-Patienten mit kleinzelligem Lungenkrebs im ausgedehnten Stadium (ES-SCLC)
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:
- Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
- Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35223
- Alabama Oncology
-
-
Arizona
-
Goodyear, Arizona, Vereinigte Staaten, 85338
- City of Hope - Phoenix
-
Tucson, Arizona, Vereinigte Staaten, 85715
- Arizona Clinical Research Center (ACRC)
-
-
Arkansas
-
Springdale, Arkansas, Vereinigte Staaten, 72762
- Highlands Oncology Group
-
-
California
-
Fountain Valley, California, Vereinigte Staaten, 92708
- Compassionate Care Research Group
-
Fullerton, California, Vereinigte Staaten, 92835
- Providence Medical Foundation
-
Glendale, California, Vereinigte Staaten, 91204
- Los Angeles Cancer Network
-
Los Alamitos, California, Vereinigte Staaten, 90720
- OPN - Oncology Physician Network
-
Los Angeles, California, Vereinigte Staaten, 90034
- Kaiser Permanente Research (Southern California)
-
Sacramento, California, Vereinigte Staaten, 95817
- UC Davis
-
-
Colorado
-
Colorado Springs, Colorado, Vereinigte Staaten, 80920
- UCHealth Memorial Hospital North
-
Greeley, Colorado, Vereinigte Staaten, 80631
- MD Anderson- North Colorado Medical Center
-
-
Florida
-
Brooksville, Florida, Vereinigte Staaten, 34613
- Advanced Cancer Treatment Centers
-
Jacksonville, Florida, Vereinigte Staaten, 32256
- Cancer Specialists North Florida
-
Miami, Florida, Vereinigte Staaten, 33140
- Mount Sinai Comprehensive Cancer Center
-
Ocala, Florida, Vereinigte Staaten, 34473
- Florida Cancer Affiliates- (Ocala Oncology - Main)
-
Orange City, Florida, Vereinigte Staaten, 32763
- Mid Florida Hematology and Oncology Center
-
Plantation, Florida, Vereinigte Staaten, 33322
- BRCR Global
-
Pompano Beach, Florida, Vereinigte Staaten, 33064
- Napa Research
-
Tamarac, Florida, Vereinigte Staaten, 33321
- Advanced Research
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96814
- Straub Benioff Medical Center
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60099
- City of Hope- Chicago
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Cancer Center of Decatur
-
Tinley Park, Illinois, Vereinigte Staaten, 60487
- Accellacare of Duly
-
-
Indiana
-
Dyer, Indiana, Vereinigte Staaten, 46311
- Northwest Cancer Centers
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40503
- Baptist Health Lexington
-
Pikeville, Kentucky, Vereinigte Staaten, 41501
- Pikeville Hospital
-
-
Louisiana
-
Alexandria, Louisiana, Vereinigte Staaten, 71301
- CHRISTUS St. Frances Cabrini Cancer Center
-
Hammond, Louisiana, Vereinigte Staaten, 70433
- Pontchartrain Cancer Center
-
-
Michigan
-
Southfield, Michigan, Vereinigte Staaten, 48075
- Henry Ford Health Providence Southfield Hospital
-
-
Minnesota
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Health Partners Cancer Center at Regions Hospital
-
-
Mississippi
-
Hattiesburg, Mississippi, Vereinigte Staaten, 39401
- Hattiesburg Clinic Hematology/Oncology
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten, 64132
- MidAmerica Division Inc., c/o Research Medical Center
-
Osage Beach, Missouri, Vereinigte Staaten, 65065
- Lake Regional
-
-
Montana
-
Billings, Montana, Vereinigte Staaten, 59102
- St. Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68106
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Vereinigte Staaten, 89502
- Renown Health
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Jersey
-
Freehold, New Jersey, Vereinigte Staaten, 03756
- Regional Cancer Care Associates LLC RCCA
-
Neptune City, New Jersey, Vereinigte Staaten, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Elmhurst, New York, Vereinigte Staaten, 11373
- Elmhurst (BRANY site)
-
Lake Success, New York, Vereinigte Staaten, 11042
- Northwell Health
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Stony Brook Cancer Center
-
Williamsville, New York, Vereinigte Staaten, 14221
- Great Lakes Cancer Care (Kaleida Health)
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44304
- Summa Health
-
Canton, Ohio, Vereinigte Staaten, 44708
- Cleveland Clinic Mercy Hospital
-
Canton, Ohio, Vereinigte Staaten, 44710
- Aultman Cancer Center
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- University Hospitals Cleveland Medical Center
-
Massillon, Ohio, Vereinigte Staaten, 44646
- Tricounty Hematology and Oncology Associates
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, Vereinigte Staaten, 19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02908
- CharterCARE (Roger Williams)
-
-
Texas
-
Corpus Christi, Texas, Vereinigte Staaten, 78404
- CHRISTUS Institute for Innovation & Advanced Clinical Care
-
Edinburg, Texas, Vereinigte Staaten, 78539
- DHR Research
-
Houston, Texas, Vereinigte Staaten, 77090
- Millennium Research and Clinical Development
-
Kingwood, Texas, Vereinigte Staaten, 77339
- Lumi Research
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Joe Arrington Cancer Research and Treatment Center
-
Tyler, Texas, Vereinigte Staaten, 75701
- The University of Texas Health Science Center at Tyler/HOPE Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84106
- Utah Cancer Specialists
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Olympia, Washington, Vereinigte Staaten, 98502
- American Oncology Network Vista Oncology Division
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Northwest Medical Specialties, PLLC
-
-
West Virginia
-
Morgantown, West Virginia, Vereinigte Staaten, 26505
- West Virginia University Cancer Institute
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Carbone Cancer Center
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Froedtert Hospital- Medical College of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Voluntary participation in clinical studies.
Male or female aged ≥ 18 years at the time of signing the ICF.
Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).
No prior systemic therapy for ES-SCLC.
Patients who have received chemoradiotherapy for previous limited stage SCLC must be treated with curative intent and have a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive stage SCLC.
At least one measurable lesion as assessed according to RECIST 1.1 within 4 weeks prior to randomization.
Every effort should be made to provide tumor tissues for the determination of PD-L1 expression.
Prior antineoplastic therapy including Chinese medicine therapy, which has been approved as antineoplastic therapy by NMPA or its instruction has antineoplastic therapy effect, must have been ≥ 2 weeks from the first dose in this study with treatment-related AEs resolved to NCI-CTCAE Grade ≤ 1 (except for Grade 2 alopecia).
An ECOG PS score of 0 or 1.
An expected survival ≥ 12 weeks.
Subjects with prior denosumab use that can and agree to switch to bisphosphonate therapy for bone metastases starting prior to randomization and throughout treatment.
Normal major organ functions.
Female patients must meet one of the following conditions: Menopause, Surgically sterilized or of child-bearing potential, must meet the following: negative serum pregnancy test within 7 days prior to randomization and agree to use birth control methods with an annual failure rate <1% or maintain abstinence. Must not be breast-feeding.
Male patients must: agree to abstinence or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use a condom or had vasectomy to prevent embryonic exposure during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence and external ejaculation are ineligible methods of contraception.
Exclusion Criteria:
Histologically or cytologically confirmed mixed SCLC.
Other active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ are acceptable.
Patients who are preparing for or have received an organ or bone marrow transplant.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed regardless of drainage frequency.
Patients with known or documented active CNS metastases and/or carcinomatous meningitis at screening. However, the following subjects are allowed to be enrolled: 1) Subjects with asymptomatic brain metastases may be included but are required to receive regular brain imaging as a site of lesion. 2) Subjects with treated brain metastases which have been stable for at least 2 weeks, with no evidence of new or enlarging brain metastases, and with discontinued steroids 3 days prior to study drug administration.
Subjects with spinal cord compression that has not been treated with surgery and/or radiotherapy.
Patients with myocardial infarction within half a year before the first dose of the study drug, poorly controlled arrhythmia.
Class III to IV cardiac insufficiency according to NYHA classification.
Subject has uncontrolled or symptomatic hypercalcemia.
Subject with peripheral neuropathy ≥ Grade 2 by CTCAE.
Human immunodeficiency virus (HIV) infection, positive test for HIV antibody.
Active or latent pulmonary tuberculosis.
Subjects with previous and concurrent interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity, as judged by the investigator.
Hepatitis B or Hepatitis C or Hepatitis B and C co-infection.
Known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
Have received treatment with live vaccines within 28 days prior to the first administration. Subjects may receive inactivated viral vaccines for seasonal influenza but may not receive live attenuated influenza vaccines via intranasal route.
Subjects requiring treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at doses equivalent to ≤ 10 mg/day of prednisone efficacy.
With any active infection requiring systemic anti-infective treatment at the time of first dose of study treatment.
Major surgery within 28 days prior to the first dose of the study drug, defined as: surgeries requiring at least 3 weeks of recovery to be able to receive treatment in this study.
Radical radiation therapy within 3 months prior to study medications. Note: Palliative radiotherapy to bone or palliative radiotherapy to superficial lesions is allowed according to local standards 14 days prior to the first dose. Radiotherapy covering more than 30% of the bone marrow area within 28 days prior to the first dose is not allowed.
The subject has previously received other antibodies/drugs against immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.
Participation in any other ongoing clinical studies, or less than 14 days from the end of the previous clinical study treatment to the start of this trial.
Known history of severe allergy to any monoclonal antibody.
Known hypersensitivity to carboplatin or etoposide.
Pregnant or lactating females.
Active use of psychotropics abuse or drug abuse.
In the judgment of the investigator, the subject has any other factors that may lead to a premature discontinuation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Serplulimab + chemotherapy
Serplulimab + chemotherapy (carboplatin-etoposide) |
Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics |
|
Aktiver Komparator: Atezolizumab + chemotherapy
Atezolizumab + chemotherapy (carboplatin-etoposide) |
Drug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
OS
Zeitfenster: A period from randomization through death regardless of causality (approximately up to 24 months).
|
Overall assessment |
A period from randomization through death regardless of causality (approximately up to 24 months).
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective response rate (ORR)
Zeitfenster: approximately up to 14 months
|
Objective response rate (ORR) (assessed by independent radiology review committee [IRRC] and the investigator based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) |
approximately up to 14 months
|
|
Progression-free survival (PFS)
Zeitfenster: approximately up to 24 months
|
Progression-free survival (PFS) (assessed by IRRC and the investigator based on RECIST 1.1) |
approximately up to 24 months
|
|
PFS2
Zeitfenster: Approximately up to 24 months
|
PFS2 (assessed by the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Duration of response (DOR)
Zeitfenster: Approximately up to 24 months
|
Duration of response (DOR) (assessed by IRRC and the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Adverse events
Zeitfenster: approximately up to 24 months
|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment. |
approximately up to 24 months
|
|
Observed concentration of HLX10 in serum
Zeitfenster: Approximately up to 24 months
|
Observed concentration of HLX10 in serum |
Approximately up to 24 months
|
|
Estimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/L
Zeitfenster: Approximately up to 24 months
|
The PK data obtained in this study will be pooled with other data from HLX10 (Serplulimab) clinical trials for further population pharmacokinetic analyses. The differences in PK exposure between American population and the obtained populations (Asian and non-Asian) will be compared through model simulation. |
Approximately up to 24 months
|
|
HLX10 anti-drug antibody (ADA)
Zeitfenster: Approximately up to 24 months
|
HLX10 anti-drug antibody (ADA) |
Approximately up to 24 months
|
|
Neutralizing antibody (NAb)
Zeitfenster: Approximately up to 24 months
|
Neutralizing antibody (NAb) positive rate |
Approximately up to 24 months
|
|
Quality of life assessment
Zeitfenster: Approximately up to 24 months
|
Lung cancer Quality of life assessment |
Approximately up to 24 months
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Exploratory Endpoint
Zeitfenster: Approximately up to 24 months
|
Potential prognostic and predictive biomarkers, including PD-L1 expression in tumor tissue and SCLC-related blood biomarker |
Approximately up to 24 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- ASTRIDE (HLX10-005-SCLC301-E)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .